---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-013095"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:36:53.097488+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Glucotrack to file IDE with FDA for implantable CBGM in Q2 2026, citing positive trial results

## Summary
- Brazil first-in-human study (Dec 2024-Jan 2025) showed MARD 7.7%, 99% data capture, and zero serious adverse events.
- Australia feasibility study started July 2025; findings are incorporated for planned US trial.
- Three US patents issued Oct/Nov 2025 covering sensor chemistry, intravascular lead, and low-power electronics.
- Expects to file IDE with FDA in Q2 2026 and initiate US clinical study in H2 2026, pending approval.
- Reinforced commercial foundation: market research, reimbursement pathway, dual-source manufacturing, seasoned leadership.

## SEC filing metadata
- accession: 0001493152-26-013095
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000149315226013095/0001493152-26-013095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000149315226013095/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-013095
- JSON: https://secwatch.observer/filing/0001493152-26-013095.json
- Plain text: https://secwatch.observer/filing/0001493152-26-013095.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.